Fig. 7
From: Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model
Representative images of the immunofluorescence staining (200 ×) of NOX2 expression in the cornea dissected from the experimental dry eye model. The RCI group showed reduced expression of NOX2, and the reduction was comparable to that in the PDE and Lifitegrast groups (white arrows). Red, NOX2; blue, nuclear DAPI staining. Scale bar: 100 μm; n = 3 per group. PDE, 1% prednisolone acetate; Lifite, 5% Lifitegrast; RCI, 1.0% RCI001; NOX2, nicotinamide adenine dinucleotide phosphate oxidase 2; DAPI, 4′,6-diamidino-2-phenylindole